Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Should You Buy?

Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Positive Trutakna Data (VERA)

Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Should You Buy?

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - What's Next?

Vera kidney drug Trutakna shows strong final results in Phase 3 trial

With the final data from the study in hand, Vera said it will seek full approval of the drug from the FDA during the fourth quarter.

Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results

Vera Therapeutics (VERA) stock jumped 4% after two-year ORIGIN3 trial data showed Trutakna slowed kidney decline to normal aging rates in IgAN patients.

Vera Therapeutics (VERA) Stock Jumps 4% on Positive Kidney Drug Trial Data

TLDR Vera Therapeutics stock rose 4% to $35.39 after releasing two-year trial data for its kidney drug Trutakna Trutakna slowed kidney decline to match normal aging rates in patients with IgA nephropathy Vera plans to file a supplemental Biologics License Application in Q4 to secure full FDA...

TRUTAKNA Cut ORIGIN 3 Kidney-Progression Risk by 76%; FDA Review Comes Next

Vera Therapeutics shares jumped 9.4% to $37.25 in Nasdaq premarket trading at 9:29 a.m. ET Tuesday after its confirmatory Phase 3 trial reported slower kidney-function loss with TRUTAKNA than with placebo. The move followed a $34.05 Monday close. The company’s September 15 ORIGIN 3 release addresses the question left open when the Food and Drug…